[Our initial experience in using allapinin in patients with paroxysmal supraventricular tachycardias].
Twenty one patients with various forms of paroxysmal supraventricular tachycardias (SVT) were treated with allapinine, a new antiarrhythmic drug. Intravenous infusion of allapinine (0.43 mg/kg) arrested the episodes of SVT in none of 7 patients. Oral administration of the drug for short-term treatment (150 mg/day) prevented the artificial induction or spontaneous occurrence of paroxysms in 10 of 16 patients. Thus, the first experience with allapinine shows its potential efficacy in the prophylactic treatment of paroxysmal SVT.
Golitsyn
S P
SP
Sokolov
S F
SF
Alikhanov
G N
GN
Malakhov
V I
VI
Smetnev
A S
AS
D000157:Aconitine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D031841:Aconitum / Q000031:analogs & derivatives*; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002304:Cardiac Pacing, Artificial; D004341:Drug Evaluation; D015716:Electrocardiography, Ambulatory; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013614:Tachycardia, Paroxysmal / Q000175:diagnosis / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; C051402:allapinin; D000157:Aconitine
Pervyĭ opyt primeneniia allapinina u bol'nykh s paroksizmal'nymi nadzheludochkovymi takhikardiiami.